Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour
ConclusionsOur results do not support repeated monitoring of IM levels on a routine basis in all patients. However, we have revealed clinical scenarios where drug measurement could be beneficial, such as for patients who have undergone gastric resection, suspicion of non-compliance, subjectively reported side effects, in elderly patients and at the time of disease progression. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - December 14, 2016 Category: Cancer & Oncology Source Type: research
Pazopanib: a novel treatment option for aggressive fibromatosis
ConclusionPazopanib might be an effective treatment option for AF. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - November 30, 2016 Category: Cancer & Oncology Source Type: research
UK guidelines for the management of soft tissue sarcomas
AbstractSoft tissue sarcomas (STS) are rare tumours arising in mesenchymal tissues, and can occur almost anywhere in the body. Their rarity, and the heterogeneity of subtype and location means that developing evidence-based guidelines is complicated by the limitations of the data available. However, this makes it more important that STS are managed by teams, expert in such cases, to ensure consistent and optimal treatment, as well as recruitment to clinical trials, and the ongoing accumulation of further data and knowledge. The development of appropriate guidance, by an experienced panel referring to the evidence available...
Source: Clinical Sarcoma Research - November 14, 2016 Category: Cancer & Oncology Source Type: research
Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series
ConclusionThese results on the use of pazopanib and sunitinib in chordoma are promising, with an objective response on sunitinib and a median progression free interval of 8.5 months (range 3–15 months), comparable to that of imatinib, in the pazopanib subgroup. However further research is needed to assess the definite role of VEGFR inhibitors in chordoma. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - October 31, 2016 Category: Cancer & Oncology Source Type: research
Outcome and the effect of age and socioeconomic status in 1318 patients with synovial sarcoma in the English National Cancer Registry: 1985 –2009
ConclusionsSynovial sarcoma in children/teenagers compared with adults, have a similar clinical presentation in this population-based series, but a superior outcome. The finding of socioeconomic deprivation affecting outcome in SS needs further exploration in a complete and contemporary dataset, where all prognostic variables are present. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - October 13, 2016 Category: Cancer & Oncology Source Type: research
High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas
ConclusionsHigh expression of PSME1 is associated with poor metastasis-free survival in soft tissue leiomyosarcoma patients, and might be used as an independent prognostic biomarker. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - September 30, 2016 Category: Cancer & Oncology Source Type: research
Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone
AbstractDenosumab is a monoclonal antibody to RANK ligand approved for use in giant cell tumour (GCT) of bone. Due to its efficacy, Denosumab is recommended as the first option in inoperable or metastatic GCT. Denosumab has also been used pre-operatively to downstage tumours with large soft tissue extension to allow for less morbid surgery. The role of Denosumab for conventional limb GCT of bone is yet to be defined. Further studies are required to determine whether local recurrence rates will be decreased with the adjuvant use of Denosumab along with surgery. The long term use and toxicity of this agent is unknown as is t...
Source: Clinical Sarcoma Research - September 13, 2016 Category: Cancer & Oncology Source Type: research
Solitary fibrous tumour presenting with a single bone metastasis: report of six cases and literature review
ConclusionsThis small series in a relatively rare histology suggests that isolated, possibly late, bone metastases are a plausible scenario, in particular in meningeal SFT. Notably, new bone lesions in a patient with a history of SFT should be always investigated. Exclusive local treatments may be an option, though collection of such series would be needed to define the best treatment strategy. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - August 31, 2016 Category: Cancer & Oncology Source Type: research
Primary intraosseous meningioma: an osteosclerotic bone tumour mimicking malignancy
ConclusionsPIM is a rare tumour which needs to be distinguished from primary/secondary osteosclerotic calvarial bone tumours. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - August 13, 2016 Category: Cancer & Oncology Source Type: research
Dendritic and mast cell involvement in the inflammatory response to primary malignant bone tumours
ConclusionTumours that contain a heavy inflammatory cell response, which includes DCs, TAMs and T lymphocytes, may be more amenable to immunomodulatory therapy. MCs are present mainly at the tumour edge and are likely to contribute to osteolysis and tumour invasion. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - July 31, 2016 Category: Cancer & Oncology Source Type: research
Predictors of survival in patients with sarcoma admitted to the intensive care unit
Conclusions
Our results suggest that patients that are admitted to the ICU for respiratory failure, cardiac arrest, septic shock, acute renal failure or acidosis and also have a high SOFA score with subsequent worsening in the ICU have poor prognosis. Based on the retrospective data which needs further validation we can recommend that judicious approach should be taken in patients with predictors of poor survival before subjecting them to aggressive treatment. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - July 18, 2016 Category: Cancer & Oncology Source Type: research
Patterns of care for patients with advanced soft tissue sarcoma: experience from Australian sarcoma services
Conclusions
This is the first detailed study outlining patterns of care for Australian patients with advanced STS managed at sarcoma services. These data highlight a particular area of weakness in the lack of clinical trials for sarcoma patients and also serve as an important reference point for understanding how practice may change over time as treatment options evolve. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - July 10, 2016 Category: Cancer & Oncology Source Type: research
Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study
Conclusions
Our results do not support p-IGF-1R and MMP3 evaluation in non-selected GIST patients but evaluation of this immunophenotype in WT and mutant PDGFR mutation in larger group of GIST patients, deserve merits. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - June 28, 2016 Category: Cancer & Oncology Source Type: research
Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma
Abstract
Sarcomas are a heterogeneous group of mesenchymal malignancies. In recent years, studies have demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of sarcomas. However, when used as monotherapy in the clinical setting, these targeted antiangiogenic agents have only provided modest survival benefits in some sarcoma subtypes, and have not been efficacious in others. Preclinical and early clinical data suggest that the addition of conventional chemotherapy to antiangiogenic agents may lead to more effective therapies for patients wit...
Source: Clinical Sarcoma Research - June 6, 2016 Category: Cancer & Oncology Source Type: research
A Korean single-center, real-world, retrospective study of first-line weekly paclitaxel in patients with metastatic angiosarcoma
Conclusions
In this retrospective study, first-line chemotherapy with weekly paclitaxel demonstrated clinically relevant efficacy and tolerability in unselected Korean patients with metastatic angiosarcoma. It is encouraging that response rate and PFS for Korean patients were similar to those reported in Western reports. (Source: Clinical Sarcoma Research)
Source: Clinical Sarcoma Research - May 4, 2016 Category: Cancer & Oncology Source Type: research
